FR2738486A1 - Cell extracts from plant of Iridaceae family - Google Patents

Abstract

Extract of cells (I) of \- 1 plant of the Iridaceae family, obtd. by in vitro culture, is new. Also claimed are compsns. comprising:(1) (I) and \- 1 prod. having an irritant effect, or(2) (I) and a cpd. which reduces the synthesis, liberation and/or activity of \- 1 inflammation mediator excluding steroidal and non-steroidal antiinflammatory agents.

Description

The present invention relates to the use of at least one extract of at least one
Iridacea in a cosmetic composition as an antagonist of the peptide derived from calcitonin (known as Calcitonin Gene Reiated Peptide or CGRP). The invention also relates to the use of said extract for the preparation of a pharmaceutical composition, more particularly a dermatological composition, intended for treating disorders associated with an excess of synthesis and / or release of CGRP.

CGRP is a polypeptide chemical element developed and released by a nerve ending.

The location of the CGRP is specific to sensitive nerve fibers (fibers
VS). Thus, very many organs or tissues receive afferents of CGRP neurons, these include the salivary glands, the stomach, the pancreas, the intestine, the cardiovascular system, the thyroid gland and the skin.

Due to the ubiquitous distribution of CGRP, numerous disorders are associated with an excess of synthesis and / or release of CGRP.

 These include respiratory and inflammatory diseases, allergic diseases and skin disorders, especially dermatological conditions such as eczema, prurigo, rosacea.

The use of CGRP antagonists is one of the effective alternative treatments for all of the conditions listed above.

By CGRP antagonist is meant any compound capable of partially or even completely inhibiting the biological effect of CGRP.

In particular, for a substance to be recognized as a CGRP antagonist, it must induce a coherent pharmacological response (including or not its attachment to the CGRP receptor) in particular in one of the following tests:
+ the antagonist substance must decrease the vasodilation induced by capsaicin and by an antidromic electrical stimulation (applied to an afferent nerve)
+ the antagonist substance must cause inhibition of the release of CGRP by the sensitive nerve fibers and / or
+ the antagonist substance must cause an inhibition of the contraction of the smooth muscle of the vas deferens induced by CGRP.

Among the known CGRP antagonists, there may be mentioned for example CGRP 837 (amino acid sequence 8 to 37 of the N-terminal part of CGRP), or even anti-CGRP antibodies.

To date, it has not been envisaged or even suggested that an extract of at least one
Iridacea may have a CGRP antagonistic activity.

The Applicant has discovered that an extract of at least one Iridaceae meets the characteristics defined as characterizing a CGRP antagonist and can therefore be used as a CGRP antagonist.

Thus, the invention relates to the use of at least one extract of at least one
Iridacea as a CGRP antagonist in a cosmetic composition.

The invention also relates to the use of at least one extract of at least one
Iridacea for the preparation of a pharmaceutical composition, more particularly a dermatological composition, intended for treating disorders associated with an excess of synthesis and / or release of CGRP.

The extract of at least one Iridaceae can be any extract prepared from plant material from the Iridaceae family.

The composition may contain at least one extract of at least one Iridaceae obtained from plant material obtained from a whole plant cultivated in vivo or derived from culture in vitro.

The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.

The term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.

It is thus possible, for example, according to the invention to use an extract from the roots of at least one Iridaceae cultured in vitro or else an extract from undifferentiated cells from at least one Iridaceae.

Preferably an extract obtained from plant material cultivated in vitro is used and even more preferably an extract obtained from undifferentiated cells cultivated in vitro.

By undifferentiated plant cells is meant any plant cell having none of the characteristics of a particular specialization and capable of living by itself and not in dependence on other cells. These undifferentiated plant cells are possibly capable, under the effect of an induction, of any differentiation in accordance with their genome.

According to the chosen culture method, and in particular according to the chosen culture medium, it is possible to obtain, from the same explant, undifferentiated plant cells having different characters.

The Iridaceae (or Iridae) family has around 750 species.

Plants of the Iridaceae family are mainly used for their aromatic and ornamental properties.

Among the genera of Irridaceae which can be used according to the invention, mention may be made, by way of example, of the genera Romulea, Crocus, Iris, Gladiolus, Sisyrinchium or else
Hermodactylus.

As plant material which can be used, mention may be made of that coming from lris germanica, lris florentina, iris pallida, Crocus versicolor, Romulea bulbucodium or even from Gladiolus communies.

More particularly according to the invention, plant material from the genus Iris, more particularly from iris pallida, is used.

Any extraction method known to a person skilled in the art can be used according to the invention.

Mention may in particular be made of alcoholic extracts, in particular ethanolic extracts, hydroalcoholic extracts.

One can also use an extract prepared by the method described in French patent application No. 95-02379.

Thus, in a first step the plant material is ground in a cold aqueous solution, in a second step the particles in suspension are removed from the aqueous solution obtained from the first step, and in a third step the aqueous solution obtained from the second step.

This aqueous solution corresponds to the extract.

On the other hand, the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at -20 ° C.), followed by an aqueous extraction repeating the second and third steps described above.

An example of preparation of extract usable according to the invention is given elsewhere in the examples.

We have also seen in the text examples of disorders linked to an excess of synthesis and / or release of CGRP.

Thus, according to a particular aspect, the invention relates to the use of at least one extract of at least one Iridaceae in a cosmetic composition or for the preparation of a pharmaceutical composition intended for treating respiratory and inflammatory diseases, allergic diseases or skin disorders including in particular dermatological diseases such as eczema, prurigo, rosacea, severe pruritus, acne, leg ulcers, psoriasis, pustules, stretch marks.

In the field of skin disorders, it is known that certain skins are more sensitive than others. However, the symptoms of sensitive skin have so far been poorly characterized and the problem of this skin has therefore been ill defined; no one knew exactly the process involved in the sensitivity of the skin. Some thought that sensitive skin was skin that reacted to cosmetic products, others that it was skin that reacted to several external factors, not necessarily linked to cosmetic products. Sensitive skin was also assimilated to allergic skin.

Tests have been developed to identify sensitive skin, for example tests with lactic acid and with DMSO which are known to be irritants: see for example the article by K. Lammintausta et al., Dermatoses, 1988, 36, pages 4549; and the article by T. Agner and J. Serup, Clinical and
Experimental Dermatology, 1989, 14, pages 214-217.

Due to the ignorance of the characteristics of sensitive skin, it was until now very difficult if not impossible to treat them. In fact, they were treated indirectly, for example by limiting in cosmetic or dermatological compositions the use of products with an irritant nature such as surfactants, preservatives or perfumes as well as the use of certain cosmetic or dermatological active agents.

After numerous clinical tests, the applicant has been able to determine the symptoms associated with sensitive skin. These symptoms are in particular subjective signs, which are essentially dysaesthetic sensations. By dysesthetic sensations is meant more or less painful sensations felt in a skin area such as tingling, tingling, itching or itching, burning, heating, discomfort, tightness. Symptoms related to little can also be microvascular manifestations of skin tissue such as erythema.

The Applicant has also been able to show that sensitive skin is not allergic skin. Indeed, allergic skin is skin that reacts to an external agent, an allergen, which triggers an allergic reaction. It is an immunological process which only occurs when an allergen is present and which only affects sensitized subjects. The essential characteristic of sensitive skin is, according to the applicant, on the contrary, a mechanism of response to external factors, which can concern any individual, even if so-called sensitive skin individuals react to it faster than the others. This mechanism is not immunological, it is aspecific.

The Applicant has found that sensitive skin can be divided into two main clinical forms, irritable and / or reactive skin, and intolerant skin.

Irritable and / or reactive skin is skin that reacts with pruritus, that is, by itching, or by tingling, to various factors such as the environment, emotions, food, wind, friction, razor, soap, surfactants, hard water with a high concentration of lime, temperature variations or wool. In general, these signs are associated with dry skin with or without sores, or with skin that has an erythema.

Intolerant skin is skin that reacts with sensations of heating, tightness, tingling and redness, to various factors such as the environment, emotions, food and certain cosmetic products. In general, these signs are associated with hyperseborrheic or acne-prone skin with or without sores, and erythema.

"Sensitive" scalps have a more unequivocal clinical semiology: the sensations of pruritus and tingling and heating are essentially triggered by local factors such as friction, soap, surfactants, hard water with a high concentration of limestone, shampoos or lotions. .

These sensations are also sometimes triggered by factors such as the environment, emotions and food. Erythema and hyperseborrhea of the scalp and dandruff are frequently associated with the above signs.

In addition, in certain anatomical regions such as the large folds (inguinal, genital, axillary, popliteal, anal, submammary, folds of the elbow) and the feet, the sensitive skin results in itchy sensations and / or dysesthetic sensations (heating , tingling) linked in particular to sweat, friction, wool, surfactants, certain cosmetic preparations, hard water with a high concentration of lime and temperature variations.

To determine whether a skin is sensitive or not, the applicant has also developed a test. Indeed, after having carried out a large number of tests in order to define sensitive skin, she surprisingly found that there was a link between people with sensitive skin and those who reacted to a topical application of capsaicin.

The capsaicin test consists of applying 0.05 ml of a cream comprising 0.075% capsaicin to approximately 4 cm2 of skin and noting the appearance of subjective signs caused by this application, such as tingling, burning and itching. In subjects with sensitive skin, these signs appear between 3 and 20 minutes after application and are followed by the appearance of an erythema which begins at the periphery of the application area.

Until now, capsaicin has been used as a medicine, especially to treat shingles pain. Capsaicin causes a release of neuropeptides, and in particular of CGRP which comes from nerve endings of the epidermis and dermis. The Applicant has found that the pathophysiological pattern common to all the states of sensitive skin is linked to a great ability to release neuropeptides and more particularly
CGRP in the skin. The dysesthetic manifestations which are caused by their release are called "neurogenic".

No one had so far established a link between CGRP and sensitive skin.

The clinical signs of sensitive skin are essentially subjective: tingling, tingling, pruritus, tightness, overheating, and they are sometimes associated with erythema. These signs are due to specific non-specific factors. Symptoms appear mainly localized on the face, neck and scalp, but can also appear all over the body.

The Applicant has thus discovered that one of the essential characteristics of sensitive skin is linked to the release of CGRP and therefore that the use of CGRP antagonists can make it possible to obtain a preventive and curative effect for sensitive skin.

To treat sensitive skin, the applicant has therefore considered using CGRP antagonists. It has in fact surprisingly found that the incorporation of a CGRP antagonist in a composition intended for topical use makes it possible to avoid irritation and / or dysesthetic sensations and / or pruritus of the skin and / or erythema.

The invention therefore relates more particularly to the use of at least one extract of at least one Iridaceae in a cosmetic composition or for the preparation of a pharmaceutical composition intended for treating sensitive skin.

A more particular subject of the present invention is the use of at least one extract of at least one Iridaceae in a cosmetic composition or for the preparation of a pharmaceutical composition intended for preventing and / or combating skin irritations and / or scabs and / or erythema and / or overheating sensations and / or dysesthesia and / or pruritus of the skin and / or mucous membranes.

According to the invention, the extract of at least one Iridaceae is used in an amount representing from 0.001% to 20% of the total weight of the composition and preferably in an amount representing from 0.1% to 10% of the total weight of the composition.

The extract of at least one Iridaceae is used in a composition which must be ingested, injected or applied to the skin (on any cutaneous zone of the body), the hair, the nails or the mucous membranes (buccal, jugale, gingival, genital) , conjunctiva). Depending on the mode of administration, the composition according to the invention can be in all the dosage forms normally used.

For topical application to the skin, the composition may take the form in particular of an aqueous or oily solution or of a dispersion of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a phase fatty in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft consistency of the aqueous or anhydrous cream or gel type, or of microcapsules or microparticles, or of vesicular dispersions of the ionic type and non-ionic. These compositions are prepared according to the usual methods.

They can also be used for the hair in the form of aqueous, alcoholic or hydroalcoholic solutions, or in the form of creams, gels, emulsions, foams or also in the form of aerosol compositions also comprising a propellant under pressure.

For injection, the composition may be in the form of an aqueous, oily lotion or in the form of a serum. For the eyes, it can be in the form of drops and for ingestion, it can be in the form of capsules, granules of syrups or tablets.

The amounts of the various constituents of the compositions according to the invention are those conventionally used in the fields considered.

These compositions constitute in particular cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for large anatomical folds or for the body (for example day creams, night creams, cleansing creams, foundation creams, sunscreen creams), fluid foundations, make-up removal milks, body protection or care milks, anti-sun milks, lotions, gels or foams for care of the skin, such as cleansing lotions, sunscreen lotions, artificial tanning lotions, bath compositions, deodorant compositions comprising a bactericidal agent, aftershave gels or lotions, depilatory creams, compositions against insect bites, pain relieving compositions, compositions for treating certain skin diseases such as eczema, leg ulcers, rosacea, psoriasis, lichens, severe pruritus res pustules, stretch marks.

The compositions according to the invention may also consist of solid preparations constituting soaps or cleaning bars.

The compositions can also be packaged in the form of an aerosol composition also comprising a propellant under pressure.

The extract of at least one Iridaceae used according to the invention can also be incorporated into various compositions for hair care, and in particular shampoos, styling lotions, treating lotions, styling creams or gels, compositions dyes (in particular oxidation dyes) possibly in the form of coloring shampoos, restructuring hair lotions, perm compositions (in particular compositions for the first stage of a perm), fall prevention lotions or gels, shampoos anti parasitic, etc.

The compositions can also be for oral use, for example a toothpaste. In this case, the compositions may contain adjuvants and additives customary for compositions for buccal use and in particular surfactants, thickening agents, humectants, polishing agents such as silica, various active ingredients such as fluorides, in particular particularly sodium fluoride, and optionally sweetening agents such as sodium saccharinate.

When the composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition. The oils, waxes, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic field.

The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition. The emulsion may, in addition, contain lipid vesicles.

When the composition is an oily solution or gel, the fatty phase can represent more than 90% of the total weight of the composition.

In a known manner, the cosmetic composition may also contain adjuvants customary in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and coloring matters. The amounts of these various adjuvants are those conventionally used in the cosmetic field, and for example from 0.01% to 10% of the total weight of the composition.

These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.

As oils or waxes which can be used in the invention, there may be mentioned mineral oils (petroleum jelly oil), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils ( Purcellin oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers), beeswax, carnauba or paraffin. Fatty alcohols and fatty acids (stearic acid) can be added to these oils.

As emulsifiers which can be used in the invention, there may be mentioned for example glycerol stearate, polysorbate 60 and the mixture of PEG-6 / PEG-32 / Glycol
Stearate sold under the name of TefoseR 63 by the company Gattefosse.

As solvents which can be used in the invention, mention may be made of lower alcohols, in particular methanol and isopropanol, propylene glycol.

As hydrophilic gelling agents which can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylatealkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose, polyethylene.

The composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts and hydroxy acids.

As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives can be used.

According to the invention, it is possible, inter alia, to combine at least one extract of at least one Iridaceae with other active agents intended in particular for the prevention and / or treatment of skin conditions. Among these active agents, there may be mentioned by way of example:
agents modulating differentiation and proliferation and skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradiol,
Kojic acid or hydroquinone;
- antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class;
- antiparasitics, in particular metronidazole, crotamiton or pyrethroids;
- antifungals, in particular compounds belonging to the class of imidazoles such as econazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or octopirox;
- antiviral agents such as acyclovir;
- steroidal anti-inflammatory agents, such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid , Acetaminophen or glycyrrhetinic acid;
- anesthetic agents such as lidocaine hydrochloride and its derivatives;
- antipruritic agents such as thenaldine, trimeprazine or cyproheptadine;
- keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and generally fruit acids, and n-octanoyl-5-salicylic acid;
- anti-free radical agents, such as alpha-tocopherol or its esters, superoxide dismutases, certain metal chelators or ascorbic acid and its esters;
- antiseborrheics such as progesterone;
- anti-dandruff agents such as octopirox or zinc pyrithione;
- anti-acne drugs such as retinorque acid or benzoyl peroxide.

Thus, according to a particular embodiment, the invention relates to the use of at least one extract of at least one Iridaceae in a composition comprising at least one agent chosen from antibacterial, antiparasitic, antifungal, antiviral anti-inflammatory, antipruritic agents , anesthetics, keratolytics, anti-free radicals, anti-seborrheic, anti-dandruff, anti-acne and / or agents modulating differentiation and / or proliferation and skin pigmentation.

The following examples and compositions illustrate the invention without limiting it in any way. In the compositions the proportions indicated are percentages by weight
Example 1: Preparation of an lris pallida extract:
Undifferentiated irris pallida cells cultured in vitro under axenic conditions are recovered after culturing in an Erlenmeyer flask or in a fermenter by filtration through a 50 μm sieve. To 55 g of fresh material thus obtained, 27.5 ml of demineralized water are added. The whole is ground (Potter, Ultra Turax ...) at
Turax at 24000 rpm for 1 minute at 4 "C (ice bath). The ground material is centrifuged 15 at 10000 G at 4" C. The supernatant is filtered at 0.22 μm (sterilizing filtration).

The extract thus prepared is stored at 4 "C. It contains approximately 15 g of dry matter per liter.

Concerning the whole plant, the fresh material to be treated is brought back according to the dry weight to put in the same extraction conditions as for in vitro. The different parts of the plant are removed according to the relative weight of each part of it. The cold treatment makes it possible to freeze the enzymatic activities, the sterilizing filtration avoids the degradation of the active ingredients by the microorganisms of the environment. Finally, the water vehicle is compatible with ex vivo receptors and facilitates cosmetic or pharmaceutical formulations.

Example 2: Pharmacological activity of the extract of Example 1:
Measurement of the receptive affinity of the extract of undifferentiated cells of lris pallida for the human NK1 receptor (receptor to human substance P): 1) The measurement of the receptive affinity of the extract of undifferentiated cells of lris Pallia for the human NK1 receptor was carried out according to the method described in the article: Heuillet, E. et al, J. Neurochem. , 60, 1993, 868876.

The extract is tested at concentrations of 0.5%, <RTI ID = 13 are subjected to an initial tension of 1 g. An equilibration period of at least 60 minutes, during which the physiological solution is renewed several times and the initial tension readjusted, is then respected.

Following this period, electrical stimulation is applied to the smooth muscle of vas deferens, the addition of the extract is carried out after stabilization of the contractile response induced by this stimulation, ie approximately 30 minutes.

The experiments are conducted in the continuous presence of thiorphan (104 M) to inhibit the degradation of CGRP or its analogs by the endopeptidases presented on this tissue.

Each preparation is exposed to hCGRP <x (CGRP analog) at a concentration of 104 M to obtain a control inhibitory response.

After stabilizing this response, increasing concentrations of iris pallida extract or hCGRPa are tested cumulatively, recovery of contractions by these compounds indicating an antagonistic effect on CGRP receptors.

The iris pallida extract is tested at the following 3 concentrations: 0.5%, 1% and 5% of its initial concentration.

The results obtained are compared with those of the reference molecules. The number of preparations used in each case is 2 (n = 2).

After prior inhibition of the contractions by hCGRPo, the iris pallida extract allows their recovery, an effect qualitatively identical to that exerted by hCGRPa.

A 50% inhibition of the activity of hCGRPa is obtained at the concentration of 0.8% in extract.

Conclusions:
The extract of undifferentiated cells from lris pallida has an affinity for the CGRP receptor and exerts a specific CGRP antagonist activity.

Example 3:
Examples of formulations illustrating the invention. These compositions were obtained by simple mixing of the various components.

Composition 1: Make-up removing lotion for the face
Extract from Example 1 5.00
Antioxidant 0.05
Isopropanol 40.00
Preservative 0.30
Water qs 100%
Composition 2: Gel for facial care
Extract from Example 1 0.50
Hydroxypropylcellulose (Klucel H sold by the company Hercules) 1.00
Antioxidant 0.05
Isopropanol 40.00
Preservative 0.30
Water qs 100%
Composition 3: Face care cream (oil in water emulsion)
Extract from Example 1 2.00
Glycerol stearate 2.00
Polysorbate 60 (Tween 60 sold by ICI) 1.00
Stearic acid 1.40
Triethanolamine 0.70
Carbomer 0.40
Liquid fraction of shea butter 12.00
Perhydrosqualene 12.00
Antioxidant 0.05
Perfume 0.5
Preservative 0.30
Water qs 100%
Composition 4: Shampoo
Extract from Example 1 0.5
Hydroxypropylcellulose (Klucel H sold by the company Hercules) 1.00
Perfume 0.50
Preservative 0.30
Water qs 100%
Composition 5: Pain relief gel
Extract from Example 1 5.00
Hydroxypropylcellulose (Klucel H sold by the company Hercules) 1.00
Antioxidant 0.05
Lidocaine hydrochloride 2.00
Isopropanol 40.00
Preservative 0.30
Water qs 100%
Composition 6: Anti-wrinkle care cream for the face (oil / water emulsion)
Extract from Example 1 0.15
Glycerol stearate 2.00
Polysorbate 60 (Tween 60 sold by ICI) 1.00
Stearic acid 1.40
N-octanoyl-5-salicylic acid 0.50
Triethanolamine 0.70
Carbomer 0.40
Liquid fraction of shea butter 12.00
Perhydrosqualene 12.00
Antioxidant 0.05
Perfume 0.5
Preservative 0.30
Water qs 100%
Composition 7: Sun erythema care cream (oil-in-water emulsion)
Extract from Example 1 2.50
Glycerol stearate 2.00
Polysorbate 60 (Tween 60 sold by ICI) 1.00
Stearic acid 1.40
Glycyrrhetinic acid 2.00
Triethanolamine 0.70
Carbomer 0.40
Liquid fraction of shea butter 12.00
Sunflower oil 10.00
Antioxidant 0.05
Perfume 0.5
Preservative 0.30
Water qs 100%
Composition 8: Gel for the treatment of acne
Extract from Example 1 5.00
All trans retinoic acid 0.05
Hydroxypropylcellulose (Klucel H) 1.00
Antioxidant 0.05
Isopropanol 40.00
Preservative 0.30
Water qs 100%
Composition 9: Lotion for eliminating scars due to acne
Extract from Example 1 5.00
Glycolic acid 50.00
Hydroxypropylcellulose (Klucel H) 0.05
NaOH qs pH = 2.8
Ethanol qs 100%
Preservative 0.30

Claims (13)

 CLAIMS 1. Use of at least one extract of at least one Iridacea as a CGRP antagonist in a cosmetic composition. 2. Use of at least one extract of at least one Iridaceae for the preparation of a pharmaceutical composition intended for treating disorders associated with an excess of synthesis and / or release of CGRP. 3. Use according to one of the preceding claims, characterized in that the composition is intended for treating disorders of the central nervous system, respiratory disorders, allergic syndromes, inflammation, pain, gastrointestinal disorders, skin disorders, fibrosis, collagen maturation disorders cardiovascular disorders, vasospastic disorders, immunological disorders and / or urinary tract disorders. 4. Use according to one of the preceding claims, characterized in that the cosmetic or pharmaceutical composition is intended for treating sensitive skin. 5. Use according to one of the preceding claims, characterized in that the cosmetic or pharmaceutical composition is intended to prevent etiou fight against skin irritations eVou dartres eVou erythema etiou dysesthesic sensations etiou sensations of heating eVou pruritus the skin and mucous membranes. 6. Use according to one of claims 1 to 5, characterized in that the extract is an extract of whole plant. 7. Use according to any one of claims 1 to 5, characterized in that the extract is an extract of plant material obtained by culture in vitro. 8. Use according to claim 7, characterized in that the plant material is obtained by in vitro culture of undifferentiated cells. 9. Use according to any one of claims 1 to 8, characterized in that said extract is used in an amount representing from 0.001% to 20% of the total weight of the composition. 10. Use according to claim 9, characterized in that said extract is used in an amount representing from 0.1% to 10% of the total weight of the composition. 11. Use according to any one of claims 1 to 10, characterized in that said extract is an extract of plant material originating from lridaceae of a genus chosen from Romulea, Crocus, Iris, Gladiolus, Sisyrinchium or Hermodactylus. 12. Use according to claim 11, characterized in that said extract is an extract of plant material from lris. 13. Use according to claim 12, characterized in that said extract is an extract of lris pallida.